Bitop ‘made in Germany’ actives secures US distribution with Mibelle Biochemistry – CosmeticsDesign-Europe.com

Mibelle Biochemistry and Bitop, two cosmetics active ingredients manufacturers, have signed an exclusive distribution agreement for the US market.

The move will see Germany-based Bitop expanding itis global market presence, with Mibelle Biochemistry set to to supply Bitops actives from its US-based customer service centre, in White Plains New York.

By the terms of the agreement, Mibelle will process orders, provide customer service and coordinate US communications with Bitops international headquarters in Witten, Germany.

We are very happy and pleased about this co-operation, said Bitops CEO, Daniel Berger. With Mibelle Biochemistry, we have found a distribution partner who reflects our aspirations in excellent customer service.

United in values

Berger explained in a statement on the deal that Bitop and Mibelle Biochemistry share key values that will encourage the success of the new partnership, and expressed the companys anticipation of a stronger international profile in light of the deal.

Bitop and Mibelle Biochemsitry are both manufacturers of high quality actives. We share the same quality standards."

The CEO also hinted at ambitions to expand further once the actives manufacture has established itself within the US market.

Partnering with a manufacturer like Mibelle Biochemisyry is a grea opportunity for us to expand our market presence and visibility in the USA. Their US sales team is excellent and very well known in the market. This allows us to ensure the best possible technical support on site for our customers and further expansion, he confirmed.

See the article here:
Bitop 'made in Germany' actives secures US distribution with Mibelle Biochemistry - CosmeticsDesign-Europe.com

Global Market Study on Biochemistry Analyzers: Clinical Diagnostics Application Segment Projected to Retain Its … – PR Newswire (press release)

LONDON, May 29, 2017 /PRNewswire/ -- About the Report

Persistence Market Research in its latest report titled 'Biochemistry Analyzers Market: Global Industry Analysis and Forecast, 2016-2024' has presented a comprehensive research on the competition landscape in the global biochemistry analyzers market. The competition landscape portion of the global biochemistry analyzers market report begins by introducing the readers of the report to the company share analysis of all the important players operating in the global biochemistry analyzers market. This section of the report gives the breakup of the market share of all the key players operating in the global biochemistry analyzers market and observes that the market is highly fragmented owing to the presence of various companies, especially domestic players, in the global biochemistry analyzers market. In the subsequent section of the report, a competition dashboard is presented, which supplies information on various key players operating in the global biochemistry analyzers market; such as product offerings, regional presence and most important of all, strategies adopted by the key market players in order to succeed in the global biochemistry analyzers market. This kind of information is important for any new entrants or established players operating in the global biochemistry analyzers market as it provides insights on the kind of strategies being adopted by the leading market players so that they can emulate their success and also gauge the effectiveness of such strategies in different regions of the global biochemistry analyzers market.

Download the full report: https://www.reportbuyer.com/product/4921067/

In the subsequent sections of the competition landscape, individual information is supplied on the various key players operating in the global biochemistry analyzers market. The kind of information that is given includes company details, company description, product offerings, key financial information and key developments pertaining to the company. In addition, a strategic overview of the companies is also given that provides valuable information regarding the direction that the company is taking with respect to the market in the coming few years and how this will impact the global biochemistry analyzers market. Last but not the least, a SWOT analysis of all the key market players is also given in the competition landscape that provides deep insights regarding the key market players operating in the global biochemistry analyzers market and how the key market players are going to shape up the global market in the future with regards to their strengths and weaknesses and how they utilize the opportunities provided to them and tackle the various market threats and challenges.

Besides this, in the beginning of the report, a market forecast is given that comprises three scenarios, namely the conservative scenario, the likely scenario and the optimistic scenario. All of these three scenarios will result in different market numbers and growth rates and the report gives information why a particular scenario has been chosen as the most likely scenario in the global biochemistry analyzers market and also gives information regarding the other scenarios that may change the market forecasts, if at all, and the magnitude of the change on the forecasted market numbers and growth rates. Besides this, a section on regional biochemistry analyzers market volume (Unit Mn) analysis and forecast by product type, 2016-2024 is also given that provides an overview of the volume share in the regional biochemistry analyzers market and which region is the largest, most lucrative and fastest growing in terms of volume so that correct decisions pertaining to the global biochemistry analyzers market are taken. In addition, there is a section of the report devoted to the fully and semi-automated biochemistry analyzers price forecast by region, 2015 & 2024. This section of the report gives a price overview of the market region wise, so that important decisions on market growth and expansion can be taken by the players who wish to operate in the biochemistry analyzers market.

Another important and attractive feature of the global biochemistry analyzers report present by Persistence Market Research is the inclusion of PEST analysis. The detailed PEST analysis provided in the report gives all the important political, economic, social and technological aspects governing the global biochemistry analyzers market so that readers are fully aware of all the important factors that directly or indirectly affect the growth of the biochemistry analyzers market globally. Besides, information about the Laboratory Accreditation: Internal Quality Control (IQC), Laboratory Accreditation: External Quality Assessment Scheme (EQAS) are also given, adding more value to the report. Important guidelines by the Clinical and Laboratory Standards Institute (CLSI) are provided to enable readers to get an idea about the nuances of the global biochemistry analyzers market.

Also, in addition to all the above, the biochemistry analyzers market report contains an executive summary and also market definitions and the market taxonomy. Macroeconomic factors affecting the global biochemistry analyzers market along with the demand side drivers and supply side drivers are also given in order to give a deep overview of the global biochemistry analyzers market. Besides, restraints impacting the market along with opportunities and trends shaping up the biochemistry analyzers market also given to further add value to the report. The global biochemistry analyzers market analysis and forecast by product type, by end user, by modality, and by region is also given. This section of the report contains valuable information like Basis Point Share (BPS) analysis, Y-o-Y growth projections and market attractiveness analysis to provide in-depth insights into the global biochemistry analyzers market.

Market Segmentation

By Product Type

Semi-automated Biochemistry Analyzer Fully Automated Biochemistry Analyzer

By Application

Clinical Diagnostics Bioreactor Byproduct Detection Drug Development Applications Others

By Modality

Bench-top Floor standing

By End User

Hospitals Diagnostic Centers Pharmaceutical Companies Biotechnology Companies Academic Research Institutes Contract Research Organizations Academic Research Institutes

By Region

North America Latin America Europe Asia Pacific Download the full report: https://www.reportbuyer.com/product/4921067/

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: http://www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-market-study-on-biochemistry-analyzers-clinical-diagnostics-application-segment-projected-to-retain-its-dominance-through-2024-300465065.html

SOURCE ReportBuyer

http://www.reportbuyer.com

Follow this link:
Global Market Study on Biochemistry Analyzers: Clinical Diagnostics Application Segment Projected to Retain Its ... - PR Newswire (press release)

What We Know So Far About Grey’s Anatomy Season 14 – TV Guide (blog)

Now Playing Grey's Anatomy Season 14: Everything We Know So Far

We don't blame you if you're still recovering from the Grey's Anatomy Season 13 finale, but here at TVGuide.com, we've already got our eye on Season 14.

We know a few things about Season 14 for sure so far. First, Edwards (Jerrika Hinton) is gone for good given that Hinton has joined Alan Ball's upcoming HBO drama. Edwards' new lease on life unfortunately means an end to her life at Grey Sloan Memorial. We'll also almost certainly get a first look at the Grey's Anatomy firefighter spinoff before the new show launches in 2018.

As far as speculation goes, we're of the mind that we might be kissing Meredith (Ellen Pompeo) and Riggs' (Martin Henderson) relationship goodbye. Now that Owen's (Kevin McKidd) sister is back in the picture, we're getting serious deja vu from Season 2, when McDreamy (Patrick Dempsey) chose Meredith over his ex-wife Addison (Kate Walsh). It's a bit of a stretch to think she'll manage to pull that off again, no matter how great her relationship with Riggs is.

There's also a chance that Maggie's (Kelly McCreary) love life might take a "messy" turn according to TV Line. We're not sure how we'd feel about inserting Maggie into a love triangle with Jackson (Jesse Williams) and April (Sarah Drew) though, mostly because she deserves a win in the relationship department eventually.

Grey's Anatomy returns in the fall, and will air Thursdays at 8/7c on ABC.

Here is the original post:
What We Know So Far About Grey's Anatomy Season 14 - TV Guide (blog)

Nadal’s forehand; Muguruza’s slice: anatomy of a clay-court specialist – The Times (subscription)

Angelique Kerber, the world No 1, has already been dumped out of the French Open and, as is the custom at Roland Garros, a host of the worlds top players are expected to follow. As the only major played on clay, the contrast between the experts and the pretenders is starker than anywhere else in the world.

Forehand Most of the worlds best forehands - Rafael Nadals in particular - have been built on the western forehand grip, where the racket is held at an angle that allows the player to generate extra topspin by rotating the wrist over the ball at the point of impact. On clay, where the ball holds up off the surface, a heavy topspin forehand generates extra bounce, pushing opponents out of

Continued here:
Nadal's forehand; Muguruza's slice: anatomy of a clay-court specialist - The Times (subscription)

Anatomy and physiology of ageing 5: the nervous system – Nursing Times

Download a print-friendly PDF file of this article here

John Knight is senior lecturer in biomedical science; Yamni Nigam is associate professor in biomedical science, both at the College of Human Health and Science, Swansea University.

The nervous system controls the activities of all body organs and tissues, receiving input from sensory organs and responding via effector organs. With around 100billion interconnected neurons, the brain is an extremely complex, and still poorly understood, organ. However we do understand, to some degree, how age affects it, as well as the nervous system as a whole. This fifth article in our series on the anatomy and physiology of ageing describes the age-related changes occurring in the brain, spinal cord and peripheral nerves. These changes lead to a gradual decline in cognitive function and a range of other issues, such as reduced bladder control or postural hypotension, but in health the brain normally continues to function adequately throughout life.

Knight J, Nigam Y (2017) Anatomy and physiology of ageing 5: the nervous system. Nursing Times [online]; 113: 6, 55-58.

The nervous system, along with the endocrine system, controls and integrates the activities of all the bodys organs and tissues. It receives and processes sensory input from organs such as the eyes, ears and skin, and responds through a variety of effector organs.

The main organ of the nervous system is the brain, which, with around 100billion interconnected neurons, is extremely complex; despite decades of research, its function remains poorly understood. Ageing leads to a progressive loss of neurons and depletion of neurotransmitters (Mather, 2016), these changes are usually associated with a gradual decline in cognitive function and influenced by environmental, genetic and lifestyle factors (Nyberg et al, 2012).

The ageing brain gradually loses neurons and supporting neuroglial cells (Fig 1). Between the ages of 20 and 60, the brain loses around 0.1% of neurons per year, after which the process speeds up (Esiri, 2007). By the age of 90, brain mass will have decreased by around 11% compared with individuals in their 50s, which equates to a loss of about 150g of neural tissue (Wyss-Coray, 2016). The remaining tissues harbour an increased concentration of potentially harmful materials such as iron, aluminium and free radicals.

Aged neural tissues also show increasing pigmentation, largely due to the deposition of two pigments: one brown, lipofuscin (Ottis et al, 2012), and one black, neuromelanin (Clewett et al, 2016). Lipofuscin is linked to amyloid

protein deposition and the formation of neurofibrillary tangles. These abnormal areas of neural tissue are often present at low densities in aged brain tissue, even in the absence of disease (Wyss-Coray, 2016); however, where Alzheimers disease is present, these are at high densities.

The loss of neurons is most apparent in the cerebral cortex. The grooves (sulci) that mark the surface convolutions (gyri) of the cerebral cortex are visibly deeper in brains of older people (Fig 1). It was originally thought that the frontal lobes were particularly vulnerable to neural loss, but similar losses have been observed in other cortical regions such as the parietal lobes (Fjell et al, 2014).

Fig 1. Three age-related changes in the brain

Fig 1. Three age-related changes in the brain

Structural changes in the frontal and parietal lobes are related to poor memory. Many people in their 80s have modest levels of amyloid protein deposition and retain their memory, while individuals with higher levels typically have a poorer working (short-term) memory (Nyberg et al, 2012). However, the role of amyloid deposition in impairing memory has recently been questioned and other factors, such as accumulation of tau proteins, may play a more important role (Brier et al, 2016).

The hippocampus has a key role in memory and the acquisition of new skills. With age, it loses a significant amount of neural tissue (Burke and Barns, 2006), which may explain why activities such as learning a new language become more difficult with advancing age. Recent research indicated that navigating a computer-generated virtual environment improved spatial awareness and reduced the shrinkage of the hippocampus, both in younger and older people (Lvdn et al, 2012). Virtual reality computer programs could therefore potentially be used to reduce shrinkage in this vital brain area.

Around 35% of people over the age of 70years have gait problems; while there are many contributing factors, including age-related changes to muscles and joints, the nervous system is also implicated. The somatic motor cortex located in the frontal lobes of the brain controls the movement of muscles involved in walking. From middle age onwards the neurons in this region show signs of atrophy (Manini et al, 2013), which can contribute to gait problems, potentially reducing mobility in older people (Rosso et al, 2013).

Ageing is associated with a gradual increase in the size of the ventricles (fluid-filled chambers) in the brain (Fig 1). This is likely to result from a progressive loss of the cells that line the ventricles. Enlarged ventricles fill with more cerebrospinal fluid, and are readily observable using techniques such as magnetic resonance imaging. On average, the volume of the ventricular system increases by around 2.9% per year; this expansion appears to accelerate with age, with people over the age of 70 having a median rate of expansion of 4.25% per year (Raz and Rodrigue, 2006). Although ventricular expansion is seen in most older people, the cognitive impact of this remains unclear.

The medulla oblongata and other areas of the brainstem lose fewer neurons than other regions of the brain. The brainstem is probably the best preserved region of the brain, which probably reflects its essential role in supporting life: it controls breathing, peristalsis, heart rate and blood pressure. However, the autonomic function of the brain does decline with age and this can compromise the bodys ability to respond quickly to internal and external environmental changes (Hotta and Uchida, 2010). Both branches of the autonomic nervous system (ANS) the parasympathetic and sympathetic branches are compromised with age (Parashar et al, 2016).

These changes can negatively affect older people. For example, the blunting of baroreceptor responses increases the risk of postural hypotension, so standing up suddenly can lead to falls and injury. Another negative consequence is the gradual loss of bladder control. To control micturition, the body relies on the interplay of sensory stretch receptors and the ANS (which together monitor bladder filling) and the conscious areas of the cerebral cortex (which signals when the bladder is full). To initiate micturition, the body needs motor control of the urinary sphincter. All these elements function less well with age, and these age-related changes combine with those in other body systems such as prostate enlargement in men and weakened pelvic floor muscles in women to reduce bladder sensitivity and control (Hotta and Uchida, 2010), which can lead to continence problems.

Cerebral blood flow decreases by around 0.38% per year, equating to a 27% decline over 70years of life (Chen et al, 2011). This is a direct consequence of the age-related changes in the cardiovascular system, and may be exacerbated in patients with atherosclerotic occlusion of the carotid arteries.

The blood-brain barrier (BBB) is formed primarily of tight junctions between adjacent endothelial cells within the blood vessels in the brain. Additionally, specialised neuroglial cells called astrocytes wrap around the cerebral vessels, forming a further physical barrier between the blood and neural tissues. The BBB is essential to prevent most pathogens and many toxic materials crossing into the neural networks and pathways of the brain, but its integrity appears to diminish with age. A recent study indicates that, during normal ageing, the BBB is first weakened in the hippocampus, thereby allowing harmful substances and pro-inflammatory mediators to cross into this vital region of learning and memory. This breaching of the BBB may contribute to hippocampal shrinkage, and therefore to cognitive decline (Montagne et al, 2015).

Ageing is associated with a declining production of many neurotransmitters, including noradrenaline, glutamate, dopamine and serotonin. The decline in dopamine appears to be particularly important: dopamine modulates motor function and the acquisition of new skills, while also acting as one of the brains reward chemicals (Mather, 2016). The number of dopamine-producing neurons decreases as part of the normal ageing process, and this can adversely affect the ability to learn from past experiences. Recent studies show that many older people who boosted their levels of dopamine by taking L-DOPA (a drug normally used to treat Parkinsons disease) were learning as quickly as young adults again (Chowdhury et al, 2013).

Few studies have examined age-related changes to the spinal cord. A recent animal-model study shows an increase of cholesterol content in the ageing spinal cord, and the authors suggest this may potentially impair cord function (Parkinson et al, 2016).

Age-related changes to neurons and neuroglial cells appear to have little effect on spinal cord function. However, age-related changes to the vertebrae and intervertebral discs may increase pressure on the spinal cord and its branching nerve roots. This can slow down the conduction of nerve impulses along motor neurons, contributing to reduced muscular strength (Manini et al, 2013). Reduced sensory and motor conduction will increase the risk of injury due to poor coordination, poor balance and poor fine motor control.

With age, some peripheral neurons show a dying back (shrinkage of axonal length), loss of mitochondria and a degeneration of their insulatory myelin sheaths. Some of this damage may be caused by a rise in the concentrations of pro-inflammatory mediators in the body. The ageing body becomes less effective in clearing toxic metabolites and, as peripheral nerves are not afforded the protection of the BBB, this may contribute to peripheral nerve damage (Manini et al, 2013).

The loss of myelin slows the conduction of peripheral nerve impulses by around 5-10% (Joynt, 2000). In health, this reduction in conductivity causes few problems, but in older people with diabetes it may contribute to, and exacerbate, diabetic neuropathy. Damaged peripheral nerves are not repaired as efficiently in older people as in their younger counterparts, and some of these nerves are never repaired. This can contribute to reduced sensation and motor control.

In the absence of disease, intellectual ability can be retained throughout life. However, the gradual loss of neurons, depletion of neurotransmitters and slowing of nerve conduction may act together to slow down the processing of information. As a result, older people may take longer to complete certain tasks, and commonly experience the functional brain changes described below.

The loss of short-term and episodic memory is probably the earliest indication of age-related changes in the brain. Unlike what happens in dementia, the loss of short-term memory in the absence of disease does not affect life skills (such asthe ability to cook), but manifests as inconveniences (such as forgetting an item from the shopping list). Episodic memory (that is, remembering autobiographical events and their timings and sequence) also gradually declines in many older people (Fjell et al, 2014).

Verbal communication skills generally remain strong throughout life (Park and Reuter-Lorenz, 2009), but people over the age of 70years may have increasing problems using or recalling words. The ability to quickly name a common object usually remains stable up to the age of 70, but then declines with advancing years (Harada et al, 2013).

The progressive loss of neurons, reduction in impulse velocity and minor changes in the spinal cord lead to a slowing down of reaction times (Spirduso, 1995). This can create problems, particularly when a fast reaction is essential (for example, to step out of the way of oncoming traffic).

In England, around 22% of men and 28% of women over the age of 65 are affected by depression; in care homes, the figures are even greater, with around 40% of residents affected (Age UK, 2017).

It is almost impossible to determine whether depression in older people occurs as a normal consequence of ageing or as a result of chemical imbalances seen in types of depression that also affect younger people. Concentrations of neurotransmitters involved in lifting mood (particularly serotonin) diminish with age and this can contribute to symptoms of depression (Fidalgo et al, 2013). The Royal College of Psychiatrists estimates that >85% of depressed older people receive no help from the NHS (Age UK, 2017). Depression can often produce symptoms that mimic dementia (pseudo-dementia) and this often causes great anxiety.

On the whole, older people are less prone to emotional outbursts than younger people. This may be related to the relative structural stability of some of the brain regions linked to emotions. Most studies of the amygdalae which are heavily involved in impulsive behaviours and emotional reactions reveal little evidence of atrophy or shrinkage at a much slower rate than in other brain regions. Additionally, the amygdalae also appear to retain most of their functional activity in older age (Mather, 2016).

Because the overall neural mass reduces with age, neuroactive drugs such as antidepressants and neuroleptics can be more potent in older people. Doses normally prescribed to adults may induce confusion or delirium, and may therefore need to be adjusted.

How normal age-related changes to the brain can be distinguished from pathological changes associated with dementia (for example, Alzheimers disease) is hotly debated. The problem is that three of the main clinical features of Alzheimers disease loss of episodic memory, loss of brain tissue and amyloid deposition are also seen in apparently healthy older people with little or no evidence of dementia. However, it is generally recognised that the main risk factor for developing dementia is advancing age (Fjell et al, 2014).

Unlike cells in many other parts of the human body, most neurons do not undergo cell division so, when they dieas a result of age or injury, they are generally not replaced. Fortunately, the brain contains over 100billion interconnected neurons (the connectome) and many researchers agree that it has an in-built redundancy, known as the brain reserve. This is defined as the physical resources of the brain in terms of brain mass and number of neurons; a larger brain reserve is often associated with better outcomes after brain injury and in various neurological diseases (Tucker and Stern, 2011).

The brain reserve is not necessarily a good predictor of cognitive function (many people with normal cognition have significant brain atrophy), so the concept of cognitive reserve has emerged. People with a high cognitive reserve are able to use their brain reserve more efficiently to perform tasks, and this seems to happen through increased efficiency of functional connections between neurons (Marques et al, 2016).

Good predictors of a high cognitive reserve include high education level, high IQ, highly complex occupation and large amount of social interaction. Recent research indicates that cognitive ability may also be maintained by neural compensation, a process in which new circuits of neurons are recruited to perform tasks that were once carried out by aged ordamaged neural pathways (Steffener and Stern, 2012). In normal ageing, the brain reserve does decline but cognition ismaintained thanks to the brains in-built redundancy.

Keeping mentally active throughout life can reduce the effects of age on the nervous system (Mahncke et al, 2006), and engaging in social, sporting and mentally challenging activities can slow downthe decline in cognitive performance (Nyberg et al, 2012). It appears the more intellectually demanding and complex an individuals occupation, the better their cognitive performance in later years; however, in retirement, when the mental challenges of work are removed, this effect appears to decline.

Older people should be encouraged to engage in stimulating activities such as socialising, reading and games, which are thought to improve cognitive function and memory, as well as reduce the riskof depression. It is a common misconception that ageing naturally leads to conditions such as confusion, dementia and delirium. The human brains in-built redundancy allows it to adequately cope with the physical changes associated with ageing. Indeed, in the absence of disease, adequate mental function can be retained throughout life.

Age UK (2017)Later Life in the United Kingdom, January 2017.London: Age UK.

Brier MR et al (2016) Tau and A imaging, CSF measures, and cognition in Alzheimers disease.Science Translational Medicine;8: 338, 338ra66.

Burke SN, Barnes CA (2006) Neural plasticity in the ageing brain.Nature Reviews Neuroscience;7: 1, 30-40.

Chen JJ et al (2011) Age-associated reductions in cerebral blood flow are independent from regional atrophy.Neuroimage;55: 2, 468-478.

Chowdhury R et al (2013) Dopamine restores reward prediction errors in old age.Nature Neuroscience;16: 5, 648-653.

Clewett DV et al (2016) Neuromelanin marks the spot: identifying a locus coeruleus biomarker of cognitive reserve in healthy aging. Neurobiology of Aging; 37: 117-126.

Esiri MM (2007) Ageing and the brain. Journal of Pathology; 211: 2, 181-187.

Fidalgo S et al (2013) Serotonin: from top to bottom. Biogerontology; 14: 1, 21-45.

Fjell AM et al (2014) What is normal in normal aging? Effects of aging, amyloid and Alzheimers disease on the cerebral cortex and the hippocampus. Progress in Neurobiology; 117: 20-40.

Harada CN et al (2013) Normal cognitive aging; Clinics in Geriatric Medicine; 29: 4, 737-752.

Hotta H, Uchida S (2010) Aging of the autonomic nervous system and possible improvements in autonomic activity using somatic afferent stimulation. Geriatrics and Gerontology International; 10: Suppl 1, S127-S136.

Joynt RJ (2000) Aging and the nervous system. In: The Merck Manual of Geriatrics. West Point PA: Merck & Co.

Lvdn M et al (2012) Spatial navigation training protects the hippocampus against age-related changes during early and late adulthood. Neurobiology of Aging; 33: 3, 620.e9-620.e22.

Mahncke HW et al (2006) Memory enhancement in healthy older adults using a brain plasticity-based training program: a randomized, controlled study. Proceedings of the National Academy of Sciences of the United States of America; 103: 33, 12523-12528.

Manini TM et al (2013) Aging and muscle: a neurons perspective. Current Opinion in Clinical Nutrition and Metabolic Care; 16: 1, 21-26.

Marques P et al (2016) The functional connectome of cognitive reserve. Human Brain Mapping; 37: 9, 3310-3322.

Mather M (2016) The affective neuroscience of aging. Annual Review of Psychology; 67: 213-238.

Montagne A et al (2015) Blood-brain barrier breakdown in the aging human hippocampus. Neuron; 85: 2, 296-302.

Nyberg L et al (2012) Memory aging and brain maintenance. Trends in Cognitive Sciences; 16: 5, 292-305.

Ottis P et al (2012) Human and rat brainlipofuscin proteome. Proteomics; 12: 15-16, 2445-2454.

Parashar R et al (2016) Age related changes in autonomic functions. Journal of Clinical and Diagnostic Research; 10: 3, CC11-CC15.

Park DC, Reuter-Lorenz P (2009) The adaptive brain: aging and neurocognitive scaffolding. Annual Review of Psychology; 60: 173-196.

Parkinson GM et al (2016) Perturbed cholesterol homeostasis in aging spinal cord. Neurobiology of Aging; 45: 123-135.

Raz N, Rodrigue KM (2006) Differential aging of the brain: patterns, cognitive correlates and modifiers. Neuroscience and Biobehavioral Reviews; 30: 6, 730-748.

Rosso AL et al (2013) Aging, the central nervous system, and mobility. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences; 68: 11, 1379-1386.

Spirduso WW (1995) Physical Dimensions of Aging. Champaign, Il: Human Kinetics.

Steffener J, Stern Y (2012) Exploring the neural basis of cognitive reserve in aging. Biochimica et Biophysica Acta; 1822: 3, 467-473.

Tucker AM, Stern Y (2011) Cognitive reserve in aging. Current Alzheimer Research; 8: 4, 354-360.

Wyss-Coray T (2016) Ageing, neurodegeneration and brain rejuvenation. Nature; 539: 7628, 180-186.

Follow this link:
Anatomy and physiology of ageing 5: the nervous system - Nursing Times

Tennessee wildlife officials warn residents to be aware of bears on the move – Chattanooga Times Free Press

A fed bear is a dead bear. Humans should never feed bears. Mime Barnes, Tennessee Wildlife Resources Agency spokeswoman

Black Bear in the Great Smoky Mountains National Park

Black Bear in the Great Smoky Mountains National...

Photo by Contributed Photo /Times Free Press.

As summer approaches, activities such as hiking, camping and cookouts can bring people in close contact with black bears, and state officials want people to be aware of the dangers.

The Tennessee Wildlife Resources Agency receives more calls about black bears in the spring than any other time. It's the time of year when bears are hungry and on the move.

Wildlife officials say young bears are seeking new territory and are often unfamiliar with terrain and human inhabitants.

"Young, second-year cubs are leaving their mothers. Females won't go far to establish their territories," TWRA spokeswoman Mime Barnes said. "Sometimes their territories even overlap with their mother's."

Young male bears, however, go farther afield, leading to a higher likelihood of encounters with humans.

"We've not had any incidents," Barnes said Friday. "We've had sightings, but sightings are normal this time of year."

Obviously, a hike in the Cherokee National Forest or the Great Smoky Mountains National Park can lead to bear encounters, but so can ordinary outdoor activities for folks who live near bear habitats.

Gardening, hiking, camping and grilling increase the potential for more bear-human interactions.

Resources agency officials said many people are unsure of how to live in an area where bears are present, and they can unknowingly attract and provide for wild animals that live nearby. Attractants include bird feeders, trash, bird baths and pet food bowls with leftover food, officials said.

Don't feed bears no matter where they are encountered, because bears accustomed to food provided by humans are easily conditioned and pose a greater threat, officials said. The smell of grease on a grill, ripe vegetables in a garden, trash and bird feeders provide effortless meals for bears, and once a bear gets this easy meal, it doesn't forget.

Nuisance bears are serious problems.

"There is a lot taken into consideration before a bear is moved," Pickett County wildlife officer Craig Norris said in a resources agency statement. Officials evaluate several things, including females with cubs, the number of times a bear has caused an issue, the level of aggressiveness, the location and the nuisance concern itself. Problems are most often linked to humans, Norris said. Bears will travel impressive distances to return to an area where they easily found food.

"Euthanization isn't our goal, and it's disconcerting when we reach this level," TWRA biologist Ben Layton said. "Our goal is helping people understand that human behavior most often causes nuisance bear issues.

"People think they're protecting something or helping it when they purposefully put out table scraps or leave feeders in their yards. However, they're encouraging a dangerous situation, and in the end it causes harm to wildlife," Layton said.

Barnes said the rule is simple.

"A fed bear is a dead bear," she said of an adage repeated by state officials every season. "Humans should never feed bears."

Contact staff writer Ben Benton at bbenton@timesfreepress.com or 423-757-6569.

Here are some tips for avoiding problems with bears when enjoying the outdoors or for homeowners in rural areas:

Look large and make a lot of noise, back slowly away should you encounter a bear.

Never run from a bear.

Do not purposefully feed bears.

Store garbage in bear-proof containers or in a manner that is inaccessible to bears.

Do not feed birds between April and January when bears are most active.

Remove uneaten pet food from outside areas or feed pets indoors.

Do not add greasy foods to your compost piles or compost in bear-proof containers.

Keep cooking grills clean and stored indoors when not in use.

Report problem bears or any odd behavior to your regional TWRA office.

Visit Bebearaware.org, a national site dedicated to reducing human-bear conflicts.

Source: Tennessee Wildlife Resources Agency

Go here to read the rest:
Tennessee wildlife officials warn residents to be aware of bears on the move - Chattanooga Times Free Press

Fish and Game Traps 3 of Hanover’s Nuisance Bears – Valley News

Hanover Three juvenile bears that were initially targeted to be destroyed after two of them forced their way into a residence and later won a reprieve from Gov. Chris Sununu have been trapped and relocated.

One of the bears was captured on Saturday and two more were trapped on Sunday. All of them were captured using culvert-style bear traps set near dumpsters at Wheelock Terrace and Buck Road, according to Andrew Timmins, the state of New Hampshire Fish and Games Bear Project leader.

All released together today, Timmins said in an email on Memorial Day.

They were set free at an undisclosed location in the North Country, Timmins said, adding each one was tagged to aid in future tracking.

The bears mother hasnt been accompanying the juveniles in recent days, Timmins said, and as of Sunday evening she had not been captured. Fish and Game will resume efforts to trap her this week, he said.

While she may be spending more time out of town during breeding season, she ultimately will return to her core area and likely have her next litter of cubs in January, Timmins said.

Its been suggested the sow might leave the area if attractants, such as food and birdseed, are cleaned up, Timmins said.

But hes doubtful residents in Hanover and Lebanon will comply sufficiently before more cubs are born.

As much publicity as has been on this issue over the past week, I have seen very little improvement on the reduction of food attractants in the area, particularly on the Route 120 side, he said.

This spring, the bear family, fresh from hibernation, became notorious for wandering through a neighborhood between downtown Hanover and Mink Brook, drawn by unsecured household trash and bird feeders left out after the winter.

When two of the bears entered a Thompson Terrace home two weeks ago, Fish and Game officials announced their intent to destroy the bears, saying the animals were too accustomed to humans and were unlikely to be successfully relocated.

But public outcry over plans to euthanize the animals was swift.

More than 10,000 people, many from outside the state, signed an online petition within days to save the bears.

Meanwhile, Ben Kilham, a bear biologist in Lyme who rescues wild bears, questioned whether killing the bears was necessary. Kilham said last week that with black bear breeding season approaching, the sow would soon chase her cubs away so she could mate.

Kilham emphasized that human behavior needed to change in order to change bear behavior.

Gov. Chris Sununu ultimately stepped into the fray late last week and ordered wildlife officials to relocate the bears.

I am glad that we have been able to find a safe and humane option for these bears and I encourage residents to work with their local town officials to enact ordinances that could help avoid situations like this in the future, Sununu said in a prepared statement.

Sununus decision was praised by many, particularly Nicole Cantlin, the Enfield resident who started the online petition to save the animals.

Cantlin was present when two of the cubs were tranquilized on Sunday and posted photos of two sedated bears to her Facebook page on Monday.

I did get to see them awake before these shots and they were more like dogs than a wild animal. Its sad people have made them this way, she wrote. Hoping they can make a new life up north.

Read more:
Fish and Game Traps 3 of Hanover's Nuisance Bears - Valley News

‘This is not the end’: Using immunotherapy and a genetic glitch to … – Washington Post

The oncologist was blunt: Stefanie Johos colon cancer was raging out of control and there was nothing more she could do. Flanked by her parents and sister, the 23-year-old felt something wet on her shoulder. She looked up to see her father weeping.

I felt dead inside, utterly demoralized, ready to be done, Joho remembers.

But her younger sister couldnt accept that. When the family got back to Johos apartment in New Yorks Flatiron district, Jess opened her laptop and began searching frantically for clinical trials, using medical words shed heard but not fully understood. An hour later, she came into her sisters room and showed her what shed found. Im not letting you give up, she told Stefanie. This is not the end.

That search led to a contact at Johns Hopkins University, and a few days later, Joho got a call from a cancer geneticist co-leading a study there. Get down here as fast as you can! Luis Diaz said. We are having tremendous success with patients like you.

What followed is an illuminating tale of how one womans intersection with experimental research helped open a new frontier in cancer treatment with approval of a drug that, for the first time, capitalizes on a genetic feature in a tumor rather than on the diseases location in the body.

The breakthrough, made official last week by the Food and Drug Administration, immediately could benefit some patients with certain kinds of advanced cancer that arent responding to chemotherapy. Each should be tested for that genetic signature, scientists stress.

These are people facing death sentences, said Hopkins geneticist Bert Vogelstein. This treatment might keep some of them in remission for a long time.

In August 2014, Joho stumbled into Hopkins for her first infusion of the immunotherapy drug Keytruda. She was in agony from a malignant mass in her midsection, and even with the copious amounts of oxycodone she was swallowing, she needed a new fentanyl patch on her arm every 48 hours. Yet within just days, the excruciating back pain had eased. Then an unfamiliar sensation hunger returned. She burst into tears when she realized what it was.

As months went by, her tumor shrank and ultimately disappeared. She stopped treatment this past August, free from all signs of disease.

[Negotiating cancer: Tips from one whos done it ]

The small trial in Baltimore was pivotal, and not only for the young marketing professional. It showed that immunotherapy could attack colon and other cancers thought to be unstoppable. The key was their tumors genetic defect, known as mismatch repair (MMR) deficiency akin to a missing spell-check on their DNA. As the DNA copies itself, the abnormality prevents any errors from being fixed. In the cancer cells, that means huge numbers of mutations that are good targets for immunotherapy.

The treatment approach isnt a panacea, however. The glitch under scrutiny which can arise spontaneously or be inherited is found in just 4percent of cancers overall. But bore in on a few specific types, and the scenario changes dramatically. The problem occurs in up to 20percent of colon cancers and about 40percent of endometrial malignancies cancer in the lining of the uterus.

In the United States, researchers estimate that initially about 15,000 people with the defect may be helped by this immunotherapy. That number is likely to rise sharply as doctors begin using it earlier on eligible patients.

Joho was among the first.

***

Even before Joho got sick, cancer had cast a long shadow on her family. Her mother has Lynch syndrome, a hereditary disorder that sharply raises the risk of certain cancers, and since 2003, Priscilla Joho has suffered colon cancer, uterine cancer and squamous cell carcinoma of the skin.

Stefanies older sister, Vanessa, had already tested positive for Lynch syndrome, and Stefanie planned to get tested when she turned 25. But at 22, several months after she graduated from New York University, she began feeling unusually tired. She blamed the fatigue on her demanding job. Her primary-care physician, aware of her mothers medical history, ordered a colonoscopy.

When Joho woke up from the procedure, the gastroenterologist looked like a ghost, she said. A subsequent CT scan revealed a very large tumor in her colon. Shed definitely inherited Lynch syndrome.

She underwent surgery in January 2013 at Philadelphias Fox Chase Cancer Center, where her mother had been treated. The news was good: The cancer didnt appear to have spread, so she could skip chemotherapy and follow up with scans every three months.

[More than two-thirds of cancer mutations are due to random DNA copying errors, study says]

By August of that year, though, Joho started having relentless back pain. Tests detected the invasive tumor in her abdomen. Another operation, and now she started chemo. Once again, in spring 2014, the cancer roared back. Her doctors in New York, where she now was living, switched to a more aggressive chemo regimen.

This thing is going to kill me, Joho remembered thinking. It was eating me alive.

She made it to Jesss college graduation in Vermont that May. Midsummer, her oncologist confessed he was out of options. As he left the examining room, he mentioned offhandedly that some interesting work was going on in immunotherapy. But when Joho met with a hospital immunologist, that doctor told her no suitable trials were available.

Joho began planning to move to her parents home in suburban Philadelphia: I thought, Im dying, and Id like to breathe fresh air and be around the green and the trees.

Her younger sister wasnt ready for her to give up. Jess searched for clinical trials, typing in immunotherapy and other terms shed heard the doctors use. Up popped a trial at Hopkins, where doctors were testing a drug called pembrolizumab.

***

Pembro is part of a class of new medications called checkpoint inhibitors that disable the brakes that keep the immune system from attacking tumors. In September 2014, the treatment was approved by the FDA for advanced melanoma and marketed as Keytruda. The medication made headlines in 2015 when it helped treat former president Jimmy Carter for melanoma that had spread to his brain and liver. It later was cleared for several other malignancies.

Yet researchers still dont know why immunotherapy, once hailed as a game changer, works in only a minority of patients. Figuring that out is important for clinical as well as financial reasons. Keytruda, for example, costs about $150,000 a year.

By the time Joho arrived at Hopkins, the trial had been underway for a year. While an earlier study had shown a similar immunotherapy drug to be effective for a significant proportion of patients with advanced melanoma or lung or kidney cancer, checkpoint inhibitors werent making headway with colon cancer. A single patient out of 20 had responded in a couple of trials.

Why did some tumors shrink and others didnt? What was different about the single colon cancer patient who benefited?

Drew Pardoll, director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Hopkins, and top researcher Suzanne L. Topalian took the unusual step of consulting with the cancer geneticists who worked one floor up.

This was the first date in what became the marriage of cancer genetics and cancer immunology, Pardoll said.

[A consumers guide to the hottest field in cancer treatments immunotherapy]

In a brainstorming session, the geneticists were quick to offer their theories. They suggested that the melanoma and lung cancer patients had done best because those cancers have lots of mutations, a consequence of exposure to sunlight and cigarette smoke. The mutations produce proteins recognized by the immune system as foreign and ripe for attack, and the drug boosts the systems response.

And that one colon-cancer patient? As Vogelstein recalls, We all said in unison, He must have MMR deficiency! because such a genetic glitch would spawn even more mutations. The abnormality was a familiar subject to Vogelstein, who in the 1990s had co-discovered its role in the development of colon cancer. But the immunologists hadnt thought of it.

When the patients tumor tissue was tested, it was indeed positive for the defect.

The researchers decided to run a small trial, led by Hopkins immunologist Dung Le and geneticist Diaz, to determine whether the defect could predict a patients response to immunotherapy. The pharmaceutical company Merck provided its still-experimental drug pembrolizumab. Three groups of volunteers were recruited: 10 colon cancer patients whose tumors had the genetic problem; 18 colon cancer patients without it; and 7 patients with other malignancies with the defect.

The first results, published in 2015 in the New England Journal of Medicine, were striking. Four out of the 10 colon cancer patients with the defect and 5 out of the other 7cancer patients with the abnormality responded to the drug. In the remaining group, nothing. Since then, updated numbers have reinforced that a high proportion of patients with the genetic feature benefit from the drug, often for a lengthy period. Other trials by pharmaceutical companies have shown similar results.

The Hopkins investigators found that tumors with the defect had, on average, 1,700 mutations, compared with only 70 for tumors without the problem. That confirmed the theory that high numbers of mutations make it more likely the immune system will recognize and attack cancer if it gets assistance from immunotherapy.

The studies were the foundation of the FDAs decision on Tuesday to green-light Keytruda to treat cancers such as Johos, meaning malignancies with certain molecular characteristics. This first-ever site-agnostic approval by the agency signals an emerging field of precision immunotherapy, Pardoll said, one in which genetic details are used to anticipate who will respond to treatments.

***

For Joho, now 27 and living in suburban Philadelphia, the hard lesson from the past few years is clear: The cancer field is changing so rapidly that patients cant rely on their doctors to find them the best treatments. Oncologists can barely keep up, she said. My sister found a trial I was a perfect candidate for, and my doctors didnt even know it existed.

Her first several weeks on the trial were rough, with an early hospitalization after she cut back too quickly on her fentanyl and went into withdrawal. She still has some lasting side effects today joint pain in her knees, minor nausea and fatigue but they are manageable.

I have had to adapt to some new limits, she acknowledged. But I still feel better than I have in five years.

The FDAs decision last week was an emotional moment. Diaz, now at Memorial Sloan Kettering Cancer Center in New York, immediately texted her. We did it! he exulted.

I got chills all over my body, Joho said. To think that I was at the end of the road, with no options, and then to be part of such a change.

Her experience has prompted her to drop plans to go back into marketing. Now she wants to help patients navigate the new cancer landscape. Become an expert on your cancer is her message. Dont be passive. She encourages patients to try clinical trials.

As a cancer survivor with Lynch syndrome, Joho will be closely watched; if she relapses, she is likely to be treated again with immunotherapy. And if her mother relapses, Keytruda might now be her best chance.

Coming out the other side, I feel really lucky, Joho said. Shes also grateful for something else: A few years ago, her sister Jess was tested for the disorder that has so affected their family. She was negative.

Continue reading here:
'This is not the end': Using immunotherapy and a genetic glitch to ... - Washington Post

UCR researchers explore how the brain communicates fear – Highlander Newspaper

Courtesy of UCR Today

On May 10, Jun-Hyeong Cho, assistant professor of cell biology and neuroscience at UCR, and Woong Bin Kim, a postdoctoral researcher in Chos lab, published their study on fear memory in Journal of Neuroscience. Cho and Kim conducted studies on fear memory to understand how the brain interprets and remembers fear. They concluded that humans and animals develop adaptive fear responses to dangerous situations to survive. In addition, their research focused on the specific areas of the brain that are involved in fear memory.

Their study focused on understanding the mechanistic features of the double-projecting neurons that are sent out from the hippocampus to the amygdala and the medial prefrontal cortex (mPFC). The hippocampus encodes context cues (the set of circumstances around an event), the amygdala stores associations between a context and an aversive event, and the mPFC signals whether a defensive response is appropriate in the present context, Cho explained in an interview with the Highlander.

This study could help researchers learn more about fear-related conditions such as post-traumatic stress disorder (PTSD). According to the U.S. Department of Veterans Affairs, PTSD is a mental health problem that some people develop after experiencing or witnessing a life-threatening event, like combat, a natural disaster, a car accident, or sexual assault. Cho explained that around seven percent of Americans today suffer from PTSD, and this study proposes that it may be caused by a disruption in the natural fear-learning process.

To conduct their research, the pair used a tracing method in the brains of the mice to show the hippocampal neurons that project to different areas in the brain. The neurons are labeled with fluorescent proteins with different colors to show their movements throughout the brain. We also found neural mechanisms (are) how these double-projecting neurons efficiently convey contextual information to the amygdala and mPFC to encode and retrieve fear memory for a context associated with an aversive event, said Cho.

Cho has been an assistant professor in the cell biology and neuroscience department at UCR since 2014. Before coming to UCR, Cho was an instructor in psychiatry at Harvard Medical School from 2012-2014. Cho hopes that his continued research will uncover how the brain works in learning and fear.

Cho says that they want to continue researching about the effects of these neurons on individuals fear memory. To do this, they will selectively silence the neurons and see how it impacts the formation of fear memory. Although the two researchers have published their work so far, they hope to continue research in this field in the future.

Continue reading here:
UCR researchers explore how the brain communicates fear - Highlander Newspaper

Monday on TV: ‘Grey’s Anatomy’ producer tries to improve on … – Salt Lake Tribune (blog)

It's lavish, multi-racial and a bit of a confusing mess.

And, apparently, being Shonda Rhimes will only get you so far. ABC ordered only seven episodes of "Still Star-Crossed," and it's airing them during the summer, with a debut on Memorial Day.

Elsewhere on TV

Stanley Cup Final (6 p.m., NBC/Ch. 5): Game 1 Nashville Predators at Pittsburgh Penguins

"Michael Jackson: Searching for Neverland" (6 p.m., Lifetime): Jackson life is recalled by his bodyguards. Really.

"Gotham" (7 p.m., Fox/Ch. 13): Gordon races to save the city from the Alice Tetch virus; some of Gotham's worst villains band together.

"The Bachelorette" (8 p.m., ABC/Ch. 4): Ashton Kutcher and Mila Kunis judge a contest; Kareem Abdul Jabbar plays basketball with the guys; one bachelor betrays Rachel.

"Lucifer" (8 p.m., Fox/Ch. 13): In the Season 2 finale, Charlotte accidentally burns a man to death and Lucifer has to keep Chloe from figuring out what happened.

"American Dad" (8 p.m. TBS): The town turns on Steve after he convinces the star quarterback of the arena-football team to quit playing.

"Angie Tribeca" (8:30 p.m., TBS): Holy 'Blindspot'! A naked woman emerges from a child's backpack and doesn't remember a thing.

National Memorial Day Concert (10 p.m, Ch. 11): Recorded on Sunday.

"Leah Remini: Scientology & the Aftermath" (10 p.m., A&E): In this two-hour special, Leah Remini and Mike Rinder explore the relationship between the Church of Scientology and its critics.

See more here:
Monday on TV: 'Grey's Anatomy' producer tries to improve on ... - Salt Lake Tribune (blog)